Maki Murakami1,2, Takao Kobayashi3,2,4, Takahiko Kubo5,2, Toshiyuki Hata2,6, Satoru Takeda7,2, Hideaki Masuzaki2,8. 1. Department of Obstetrics and Gynecology, Aiwa Hospital, Kawagoe, Saitama. 2. Perinatology Committee, Japan Society of Obstetrics and Gynecology, Tokyo. 3. Department of Obstetrics and Gynecology, Hamamatsu Medical Center, Hamamatsu. 4. Japan Society of Obstetrical, Gynecological and Neonatal Hematology, Fukuoka, Japan. 5. Division of Obstetrics, Center of Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development. 6. Department of Perinatology and Gynecology, Kagawa University Graduate School of Medicine, Miki. 7. Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine. 8. Department of Obstetrics and Gynecology, Nagasaki University Faculty of Medicine, Nagasaki.
Abstract
AIM: To investigate the utility of recombinant activated Factor VII (rFVIIa) for severe post-partum hemorrhage (PPH) in Japan. METHODS: We studied 69 patients treated with rFVIIa for severe PPH; 44 patients were from the registry of Japan Society of Obstetrical, Gynecological and Neonatal Hematology, and 25 were identified by a survey of the Japan Society of Obstetrics and Gynecology. RESULTS: Overall, the mean and median blood loss were 11 835 mL and 8639 mL, respectively. Treatment before rFVIIa included transarterial embolization in 23 patients and hysterectomy in 38. Forty-two patients had a single dose, 17 had two doses, and four had three doses. The mean (± SD) single dose was 81.60 ± 16.25 µg/kg. Sixty-five patients survived, and four died. The cause of PPH in patients who died was uterine rupture plus amniotic fluid embolism in two patients, uterine cervical laceration in one, and placental abruption in one. The amount of blood loss in cases of death was 6428-43 810 mL. This suggested that whether a patient survives or not was more dependent on her general condition before and after rFVIIa treatment than on the amount of blood loss. Four patients had thromboembolic events after rFVIIa treatment (deep vein thrombosis; deep vein thrombosis plus pulmonary embolism; acute myocardial infarction; and pulmonary embolism); all of these patients recovered. CONCLUSION: The present promising results may support the utility of rFVIIa for severe PPH in Japan.
AIM: To investigate the utility of recombinant activated Factor VII (rFVIIa) for severe post-partum hemorrhage (PPH) in Japan. METHODS: We studied 69 patients treated with rFVIIa for severe PPH; 44 patients were from the registry of Japan Society of Obstetrical, Gynecological and Neonatal Hematology, and 25 were identified by a survey of the Japan Society of Obstetrics and Gynecology. RESULTS: Overall, the mean and median blood loss were 11 835 mL and 8639 mL, respectively. Treatment before rFVIIa included transarterial embolization in 23 patients and hysterectomy in 38. Forty-two patients had a single dose, 17 had two doses, and four had three doses. The mean (± SD) single dose was 81.60 ± 16.25 µg/kg. Sixty-five patients survived, and four died. The cause of PPH in patients who died was uterine rupture plus amniotic fluid embolism in two patients, uterine cervical laceration in one, and placental abruption in one. The amount of blood loss in cases of death was 6428-43 810 mL. This suggested that whether a patient survives or not was more dependent on her general condition before and after rFVIIa treatment than on the amount of blood loss. Four patients had thromboembolic events after rFVIIa treatment (deep vein thrombosis; deep vein thrombosis plus pulmonary embolism; acute myocardial infarction; and pulmonary embolism); all of these patients recovered. CONCLUSION: The present promising results may support the utility of rFVIIa for severe PPH in Japan.
Authors: F Yang; L J Kong; J W Hu; N Liu; Y F Su; Y H Li; J L Chen; Z Y Yu; Z Q Qiao; Q H Wang; M Jiang Journal: Zhonghua Xue Ye Xue Za Zhi Date: 2017-03-14